Abbott earnings drop 35 percent in 4Q
BY FRANCINE KNOWLES firstname.lastname@example.org January 23, 2013 10:40AM
Abbott had planned to abandon Its facility on Sheridan Road in North Chicago by 2014, which would have cut the company’s water useage in half | File photo
Updated: February 25, 2013 12:36PM
ABBOTT PARK — Abbott Laboratories’ earnings dropped 35 percent in the fourth quarter from a year earlier as it absorbed costs related to its spinoff of AbbVie.
Abbott earned $1.05 billion, or 66 cents per share, down from $1.62 billion, or $1.02 a share, the company said Wednesday.
Abbott completed its spinoff of its proprietary drug business New Year’s Day, retaining its nutritional products, medical devices, diagnostic tests and branded generic pharmaceuticals businesses.
Excluding special items, Abbott earned $2.4 billion or $1.51 per share, up from $2.3 billion, or $1.45 per share.
Net sales were $10.8 billion, up 4.4 percent from $10.4 billion.
Abbott said sales of proprietary pharmaceuticals rose 7 percent to $5.1 billion. Nutritional sales rose 10.8 percent to $1.7 billion, with sales in emerging markets rising double digits. Sales of core laboratory diagnostics rose 4.8 percent to $908 million, and vascular sales rose 5.7 percent to $760 million.
Abbott said it expects its full-year 2013 earnings to be $1.98 per share to $2.04 per share. It forecast special items of roughly 59 cents per share, including separation costs, cost-cutting initiatives and other expenses. Including those net specified items, it forecast earnings per share of $1.39 to $1.45.